Cybin Inc Stock Price, News & Analysis

Cybin has received FDA authorization for an Investigational New Drug (IND) application to conduct a feasibility study measuring ketamine's psychedelic effects using Kernel’s Flow technology. This innovative neuroimaging technology allows for the dynamic tracing of brain activity during psychedelic experiences, representing a significant advancement in psychedelic therapeutics. The study aims to gather real-time quantitative data, potentially enhancing the understanding of psychedelic treatments for psychiatric disorders. Cybin retains exclusive rights to any innovations derived from the study.

Cybin Inc. has completed its 74th pre-clinical study to advance its psychedelic compounds, CYB003 and CYB004, toward clinical development. Over 50 novel compounds have been evaluated, showcasing advantages like faster onset, shorter duration, and excellent bioavailability. Safety studies adhering to FDA standards have commenced, with human studies expected in early 2022. The company aims to establish a strong portfolio of psychedelic molecules for potential therapeutic applications in mental health.

Cybin Inc. (AMEX:CYBN) has filed an international patent application under the Patent Cooperation Treaty (PCT) for innovative methods of delivering psychedelic medications through inhalation. The application aims to secure patent coverage across 153 countries, enhancing the Company's intellectual property portfolio. This approach may optimize session timing, reduce drug dosages while maintaining efficacy, and provide better control during sessions. The filing is part of Cybin's ongoing development program for its proprietary psychedelic molecule, CYB004.

Cybin Inc. announces milestones achieved by its subsidiary, Adelia Therapeutics Inc., under a December 2020 contribution agreement. Adelia has met certain Year 2 Q1 milestones, leading to the issuance of $706,586.69 in Class B shares to Adelia shareholders. These shares can be exchanged for Cybin common shares at a 10 to 1 ratio starting December 2021, with phased exchange limits until December 2023. The firm focuses on advancing psychedelic therapies, aiming to enhance dosing efficacy and address unmet medical needs.

Cybin Inc. announced key management changes and engagement with ROK Consulting to enhance market communications. Dr. Amir Inamdar joined as Chief Medical Officer for European Operations, and Dr. Geoff Varty became Head of Research & Development. Lori Challenger was promoted to Chief Compliance, Ethics & Administrative Officer, while Robert Mino was named General Counsel. The engagement with ROK includes a three-month contract at $500,000 per month, plus options for shares at CDN$2.78. This aims to improve the company's engagement with financial markets.

Cybin, a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present at two investor conferences on September 30, 2021. The conferences are the Cantor Virtual Global Healthcare Conference at 2:00 PM ET and the Benzinga Healthcare Small Cap Conference at 12:15 PM ET, followed by a panel discussion on mental health therapies. Both events will be available via live webcast. Cybin is dedicated to advancing psychedelic drug development for psychiatric disorders, employing innovative drug discovery and delivery techniques.

Cybin, a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation will be available on-demand starting at 7:00 AM ET and can be accessed for 90 days via the provided link. As a leader in psychedelic therapeutics, Cybin employs innovative drug discovery platforms and treatment regimens aimed at psychiatric disorders. However, all forward-looking statements are subject to risks and uncertainties.

Cybin Inc. (NYSE AMERICAN:CYBN) announced that its subsidiary, Adelia Therapeutics, has met certain milestones for Year 1 Q3 as per a December 4, 2020 agreement. In recognition, 9,392.6 Class B shares will be issued to Adelia shareholders, valued at approximately $317,471.09. These shares can be exchanged for Cybin common shares at a ratio of 10 to 1, subject to specific timing restrictions. Cybin focuses on psychedelic therapies for psychiatric disorders, leveraging innovative drug discovery and delivery methods.

Cybin (NEO:CYBN, AMERICAN:CYBN), a biotechnology company, has filed two international patent applications under the Patent Cooperation Treaty (PCT), potentially covering 153 countries. These applications pertain to a library of phenethylamine compounds and novel psychedelic compounds identified through research. The patents aim to strengthen the CYB005 program addressing therapy-resistant psychiatric disorders. Cybin’s drug development focuses on novel drug discovery, efficient delivery systems, and treatment regimens targeting mental health needs, including major depressive disorder and alcohol use disorder.